Airmid Éireann, Ireland's open pharma data project, released version 1.6 on 7 November 2026. It adds 61,683 clinical trials with sites in India and China, the Swiss list of medicines paid for by health insurance with their prices, and Czech data on registered medicines and supply interruptions. The collection now holds 76 free datasets.
- Release: version 1.6.0, archived on Zenodo as 10.5281/zenodo.24032674.
- Size: 76 datasets and 1,998,597 records from 40 official publishers, up from 71 datasets in version 1.5.
- Trials: 6,691 ClinicalTrials.gov studies with a site in India and 54,992 with a site in mainland China.
- Swiss prices: 10,333 packs on the Specialities List, with ex-factory and retail prices, after the Federal Office of Public Health confirmed free use in writing.
- Czech data: 70,032 registered medicine packs and 84,143 supply notices from SUKL, the Czech medicines regulator.
Clinical trials in India and China
Two new datasets list every study on ClinicalTrials.gov, the U.S. National Library of Medicine registry, that has at least one site in India or in mainland China. They use the same fields as the existing Irish and European trial datasets: phase, status, lead sponsor, conditions, dates and every country involved, so a study run in several countries can be compared across all four.
| India | |
|---|---|
| Studies with a site in India | 6,691 |
| Run only in India | 3,948 |
| Recruiting now | 608 |
| Also with a site in Ireland | 206 |
| Mainland China | |
| Studies with a site in China | 54,992 |
| Run only in China | 51,341 |
| Recruiting now | 11,660 |
| Also with a site in Ireland | 309 |
The two countries look very different. In India, 2,743 of the studies, about four in ten, are multinational, and global companies are among the largest sponsors: AstraZeneca leads 246 studies, Novartis 210 and Pfizer 157, alongside Indian institutions such as the Institute of Liver and Biliary Sciences (291) and the Post Graduate Institute of Medical Education and Research, Chandigarh (271). In China, more than nine in ten studies are run only in China, and the largest sponsors are hospitals and universities, led by Sun Yat-sen University with 1,523 studies and Fudan University with 1,150. Jiangsu HengRui is the largest company sponsor, with 514.
China's activity is also growing quickly on the registry: 6,288 of the studies started in 2025, and 5,492 have started so far in 2026. In line with Airmid Éireann's privacy rule, a lead sponsor that is a named person rather than an organisation is left blank, as it is in the Irish and European datasets.
India's own registry, CTRI, and China's, ChiCTR, are not included. Neither publishes terms that allow reuse, so Airmid Éireann wrote to both on 29 October to ask for permission. No reply had arrived when 1.6 was released, and the records will only be added if permission is given in writing.
Swiss medicines and their prices
The Specialities List is the list of medicines that Switzerland's compulsory health insurance pays for, kept by the Federal Office of Public Health (FOPH). Airmid Éireann now publishes it as one dataset with a row for each pack: brand name, strength and form, active substances, ATC code, marketing authorisation holder, pack size, the ex-factory and retail prices in Swiss francs, the patient's share of the cost and the date each pack was first listed.
The 10,333 packs cover 3,375 brand names and 1,293 ATC codes. The median retail price of the 10,182 priced packs is CHF 49.15. Generic makers hold the most packs: Sandoz has 1,124, Mepha 1,095 and Spirig HealthCare 862.
Before publishing it, Airmid Éireann asked the FOPH about reuse. The FOPH replied on 4 November 2026 that the list holds no personal data and is not protected by copyright as an official document, and that "the data in the LS is therefore freely available for use for your application". The FOPH does not endorse the project.
Czech medicines and supply notices
SUKL, the State Institute for Drug Control, regulates medicines in the Czech Republic and publishes its data under open terms that allow commercial reuse if SUKL is named as the source. SUKL confirmed by email on 5 November 2026 that the data can be used under those terms. Two datasets come from it.
- Registered medicines: 70,032 packs of 7,317 products, with strength, form, route, holder, ATC code and active substances. 9,696 of the packs were supplied to the Czech market in the last six months.
- Supply notices: 84,143 notices from 31 December 2008 to 5 November 2026 on when a pack starts, pauses, ends or resumes supply, with replacements and expected return dates where the holder gave them.
The Czech data has a strong Irish link. Companies based in Ireland hold 9,983 of the registered packs, more than those based in Germany (9,159) and second only to Czech companies (17,724).
| Czech supply notices in 2026 | Notices |
|---|---|
| Supply interrupted | 1,903 |
| Supply resumed | 1,735 |
| Supply started | 759 |
| Supply ended | 680 |
For 1,655 packs the most recent notice is an interruption, and for 1,608 of those the holder named a replacement or added a note. Together with the existing EU, U.S., Canadian, French and Italian shortage datasets, this lets the same medicine be followed across several markets.
What is still waiting
Permission requests to India's CTRI, China's ChiCTR, India's drug regulator CDSCO and the Australian New Zealand Clinical Trials Registry are still unanswered, and Australia's TGA is reviewing an earlier request. The two Irish employment datasets from the Department of Enterprise remain held until their reuse terms are confirmed. Sources are only added once their terms allow it.
How to use the data
All 76 datasets are free to download at priyalifescience.com/opendata/airmid/v1 as CSV and JSON, with a search page and a catalog.json index for programs. The guide How to use Airmid Éireann open pharma data explains each dataset with examples, a copy is on Kaggle, and the code is open source on GitHub.
Frequently asked questions
Q: What is new in Airmid Éireann 1.6?
A: Clinical trials with sites in India and in mainland China from ClinicalTrials.gov, the Swiss Specialities List with prices, and Czech registered medicines and supply notices from SUKL, bringing the collection to 76 datasets and 1,998,597 records.
Q: Why are CTRI and ChiCTR records not included?
A: Neither registry publishes terms that allow its records to be reused. Airmid Éireann has asked both for permission and will only add their data if they agree in writing.
Q: Can I reuse the Czech data commercially?
A: Yes, under SUKL's open-data terms, if you name SUKL as the source, link to its terms, do not suggest that SUKL endorses your use and do not change the meaning of the data.
Q: Are the Swiss prices what a patient pays?
A: The list shows the ex-factory price and the public retail price of each pack. What a patient pays also depends on their insurance deductible and the cost share, which the list gives as a percentage.
Q: How do I cite version 1.6?
A: Use the DOI 10.5281/zenodo.24032674 for this version, or 10.5281/zenodo.23336432 for all versions, and credit each dataset's original publisher.
What comes next
The data is refreshed every week, and each new release is archived on Zenodo with its own DOI. Datasets from bodies that grant permission will be added in later releases.
Cover image: headquarters of the Swiss Federal Office of Public Health in Liebefeld, near Bern. Bundesamt für Gesundheit (Schweiz), Hadi, CC0, via Wikimedia Commons, cropped.
